Potential drug –drug interactions among U.S. adults treated with nirmatrelvir/ritonavir: A cross‐sectional study of the National Covid Cohort Collaborative (N3C)
ConclusionsOne in six of individuals receiving nirmatrelvir/ritonavir were at risk of a potential moderate or severe DDI, underscoring the importance of clinical and pharmacy systems to mitigate such risks.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Category: Drugs & Pharmacology Authors: Xuya Xiao,
Hemalkumar B. Mehta,
Jill Curran,
Brian T. Garibaldi,
G. Caleb Alexander,
National Covid Cohort Collaborative (N3C) Consortium,
Adam B. Wilcox,
Adam M. Lee,
Alexis Graves,
Alfred (Jerrod) Anzalone,
Amin Manna,
Amit Saha,
Amy Olex, Tags: RESEARCH ARTICLE Source Type: research
More News: Atorvastatin Calcium | COVID-19 | Drugs & Pharmacology | Hydrocodone | Lipitor | Norvir | Oxycodone | OxyContin | Smokers | Statin Therapy | Study | Transplants | USA Health | Zivast